Clinical Trial

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-04-01; most recent amendment 2026-02-03.
Trial Details
NCT Number NCT06350318
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: BeOne Medicines
Conditions Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma
Enrollment 43 participants
Start Date 2024-04-19
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-05